Risk of Mortality in Patients with Psoriatic Arthritis, Rheumatoid Arthritis and Psoriasis: a Longitudinal Cohort Study

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2012 Dec 25

PMID 23264338

Citations 38

Authors

Alexis Ogdie

Kevin Haynes

Andrea B Troxel

Thorvardur Jon Love

Sean Hennessy

Hyon Choi

Joel M Gelfand

Affiliations

Soon will be listed here.

Abstract

Background: There are conflicting reports in the literature of the mortality risk among patients with psoriatic arthritis (PsA). The objective of this study was to examine the risk of mortality in patients with PsA compared with matched controls, patients with psoriasis and those with rheumatoid arthritis (RA).

Methods: A longitudinal cohort study was performed in a large UK medical record database, The Health Improvement Network, among patients with PsA, rheumatoid arthritis (RA) or psoriasis with data from 1994 to 2010. Unexposed controls were matched on practice and start date within the practice for each patient with PsA. Cox proportional hazards models were used to calculate the relative hazards for death.

Results: Patients with PsA (N=8706), RA (N=41 752), psoriasis (N=138 424) and unexposed controls (N=82 258) were identified; 1 442 357 person-years were observed during which 21 825 deaths occurred. Compared with population controls, patients with PsA did not have an increased risk of mortality after adjusting for age and sex (disease-modifying antirheumatic drug (DMARD) users: HR 0.94, 95% CI 0.80 to 1.10; DMARD non-users: HR 1.06, 95% CI 0.94 to 1.19) whereas patients with RA had increased mortality (DMARD users: HR 1.59, 95% CI 1.52 to 1.66; DMARD non-users: HR 1.54, 95% CI 1.47 to 1.60). Patients with psoriasis who had not been prescribed a DMARD had a small increased risk of mortality (HR 1.08, 95% CI 1.04 to 1.12) while those who had been prescribed a DMARD, indicating severe psoriasis, were at increased risk (HR 1.75, 95% CI 1.56 to 1.95).

Conclusions: Patients with RA and psoriasis have increased mortality compared with the general population but patients with PsA do not have a significantly increased risk of mortality.

Citing Articles

Cardiovascular disease risk in patients with inflammatory arthritis nowadays still substantially elevated.

Raadsen R, Hansildaar R, Pouw L, Hooijberg F, Boekel L, Wolbink G RMD Open. 2023; 9(4).

PMID: 38053460 PMC: 10693884. DOI: 10.1136/rmdopen-2023-003485.

Early intervention in psoriasis: Where do we go from here?.

Felix P, Sampaio A, Silva B, Viana A Front Med (Lausanne). 2022; 9:1027347.

PMID: 36530901 PMC: 9751903. DOI: 10.3389/fmed.2022.1027347.

All-Cause and Cause-Specific Mortality in Psoriatic Arthritis and Ankylosing Spondylitis: A Systematic Review and Meta-Analysis.

Chaudhary H, Bohra N, Syed K, Donato A, Murad M, Karmacharya P Arthritis Care Res (Hoboken). 2021; 75(5):1052-1065.

PMID: 34788902 PMC: 9110556. DOI: 10.1002/acr.24820.

All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015-2019.

Bournia V, Fragoulis G, Mitrou P, Mathioudakis K, Tsolakidis A, Konstantonis G RMD Open. 2021; 7(3).

PMID: 34728554 PMC: 8565571. DOI: 10.1136/rmdopen-2021-001694.

Vagal Nerve Stimulation-Modulation of the Anti-Inflammatory Response and Clinical Outcome in Psoriatic Arthritis or Ankylosing Spondylitis.

Brock C, Rasmussen S, Drewes A, Moller H, Brock B, Deleuran B Mediators Inflamm. 2021; 2021:9933532.

PMID: 34135691 PMC: 8175141. DOI: 10.1155/2021/9933532.

References

Sihvonen S, Korpela M, Mustonen J, Laippala P, Pasternack A . Renal disease as a predictor of increased mortality among patients with rheumatoid arthritis. Nephron Clin Pract. 2004; 96(4):c107-14. DOI: 10.1159/000077372. View

Chisholm J . The Read clinical classification. BMJ. 1990; 300(6732):1092. PMC: 1662793. DOI: 10.1136/bmj.300.6732.1092. View

Watson D, Rhodes T, Guess H . All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol. 2003; 30(6):1196-202. View

de Lusignan S, Stephens P, Adal N, Majeed A . Does feedback improve the quality of computerized medical records in primary care?. J Am Med Inform Assoc. 2002; 9(4):395-401. PMC: 346626. DOI: 10.1197/jamia.m1023. View

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

Bjornadal L, Baecklund E, Yin L, Granath F, Klareskog L, Ekbom A . Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95. J Rheumatol. 2002; 29(5):906-12. View

Gelfand J, Troxel A, Lewis J, Kurd S, Shin D, Wang X . The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007; 143(12):1493-9. DOI: 10.1001/archderm.143.12.1493. View

Doran M, Pond G, Crowson C, OFallon W, Gabriel S . Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum. 2002; 46(3):625-31. DOI: 10.1002/art.509. View

Gladman D, Antoni C, Mease P, Clegg D, Nash P . Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005; 64 Suppl 2:ii14-7. PMC: 1766874. DOI: 10.1136/ard.2004.032482. View

10.

Myllykangas-Luosujarvi R, Aho K, Kautiainen H, Isomaki H . Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis. Clin Exp Rheumatol. 1995; 13(2):149-53. View

11.

Bursac Z, Gauss C, Williams D, Hosmer D . Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008; 3:17. PMC: 2633005. DOI: 10.1186/1751-0473-3-17. View

12.

Watson D, Rhodes T, Cai B, Guess H . Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med. 2002; 162(10):1105-10. DOI: 10.1001/archinte.162.10.1105. View

13.

Dixon W, Bansback N . Understanding the side effects of glucocorticoid therapy: shining a light on a drug everyone thinks they know. Ann Rheum Dis. 2012; 71(11):1761-4. DOI: 10.1136/annrheumdis-2012-202021. View

14.

Hall G . Validation of death and suicide recording on the THIN UK primary care database. Pharmacoepidemiol Drug Saf. 2008; 18(2):120-31. DOI: 10.1002/pds.1686. View

15.

Garcia Rodriguez L, Tolosa L, Ruigomez A, Johansson S, Wallander M . Rheumatoid arthritis in UK primary care: incidence and prior morbidity. Scand J Rheumatol. 2009; 38(3):173-7. DOI: 10.1080/03009740802448825. View

16.

Haynes K, Bilker W, Tenhave T, Strom B, Lewis J . Temporal and within practice variability in the health improvement network. Pharmacoepidemiol Drug Saf. 2011; 20(9):948-55. PMC: 3225918. DOI: 10.1002/pds.2191. View

17.

Lewis J, Schinnar R, Bilker W, Wang X, Strom B . Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2006; 16(4):393-401. DOI: 10.1002/pds.1335. View

18.

Seminara N, Abuabara K, Shin D, Langan S, Kimmel S, Margolis D . Validity of The Health Improvement Network (THIN) for the study of psoriasis. Br J Dermatol. 2010; 164(3):602-9. PMC: 3064479. DOI: 10.1111/j.1365-2133.2010.10134.x. View

19.

Sokka T, Abelson B, Pincus T . Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol. 2008; 26(5 Suppl 51):S35-61. View

20.

Mikuls T, Saag K, Criswell L, Merlino L, Kaslow R, Shelton B . Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study. Ann Rheum Dis. 2002; 61(11):994-9. PMC: 1753931. DOI: 10.1136/ard.61.11.994. View